FDA approves Enspryng for at-home thyroid eye disease treatment.
Treatment appointments can add another layer of difficulty to living with an eye condition. A new FDA approval could give some people with thyroid eye disease greater flexibility.
Genentech, part of the Roche Group, announced US approval of Enspryng (satralizumab-mwge) for adults with thyroid eye disease (TED). It becomes the first and only approved at-home subcutaneous treatment for the condition.
How does Enspryng work?
Enspryng blocks the interleukin-6 receptor, targeting a pathway involved in inflammation. Patients or caregivers can administer the treatment after training from a healthcare professional, with injections every four weeks during maintenance.
TED can cause eye bulging, double vision, pain and swelling, affecting both vision and confidence.
What did the clinical trials show?
The Phase III programme produced differing results. SatraGO-2 demonstrated improvements in eye bulging and double vision, while SatraGO-1 did not meet its primary efficacy endpoint.
Treatment also requires clinical oversight. Important risks include serious infections, increased liver enzymes and reduced neutrophil counts.
What could this mean for eyecare?
At-home administration could ease the practical demands for infusion-based care, including travel and time away from everyday commitments.
For eyecare teams, the opportunity comes with practical questions: who is suitable, what training is needed, and how will monitoring and access be organised?
Stay connected with Vision Executives.
Follow Vision Executives on LinkedIn to stay up to date with the latest eye care industry news, insights and job vacancies across ophthalmology, optometry, optical retail and medical technology.